Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer
Wang L, Gong Y, Saci A, Szabo P, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack E, Sfakianos J, Bhardwaj N, Horowitz A, Farkas A, Mulholland D, Fischer B, Oh W, Sharma P, Zhu J, Galsky M. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. European Urology 2019, 76: 599-603. PMID: 31272788, PMCID: PMC6801024, DOI: 10.1016/j.eururo.2019.06.025.Peer-Reviewed Original ResearchConceptsT cell infiltrationUrothelial cancerFGFR3 mutationsAssociated with decreased T-cell infiltrationFGFR3 alterationsResponse to PD-1/PD-L1 blockadeLow T-cell infiltrationPD-1/PD-L1 inhibitionPoor T-cell infiltrationPD-1/PD-L1 blockadeResponse rateMetastatic urothelial cancerSingle-agent activityPD-1/PD-L1Tumor mutational burdenNon-cross-resistantTumors harboring mutationsFGFR3 mutation statusHypothesis-generating dataSimilar to patientsResponse to treatmentBiomarkers of resistanceGrowth factor-betaStatistically significant differenceMetastatic UC
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply